newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow

  • IGC Pharma will present seven scientific talks at the Alzheimer's Association International Conference (AAIC) 2026 in London from July 12-15, 2026.
  • The presentations highlight patent-pending agentic automation, speech-based cognitive models, EHR mining, & predictive analytics for Alzheimer's discovery.
  • The company's AI strategy focuses on data harmonization, biomarker identification, & clinical workflow optimization.
  • AHA™, a proprietary agentic harmonization assistant, reduced harmonization time from 28 hours to 2.5 hours (a 90% reduction) in internal testing of a 100-variable workflow.
  • Speech & audio biomarkers are being evaluated using multilingual deep-learning models for non-invasive cognitive decline screening.
  • Electronic health record mining applies machine learning to routine medical records for dementia detection & clinical trial recruitment.
  • Multi-omics & topological data analysis uses graph neural networks to explore neuropsychiatric pathways for targeted therapeutic development.
  • Lead asset IGC-AD1 is in the Phase 2 CALMA trial for agitation associated with Alzheimer's dementia.
  • The CALMA trial has reached 100% of its baseline randomization target, with the company completing over-enrollment & proceeding to follow-up activities.
  • IGC Pharma intends to use its AI portfolio to inform future Phase 3 & registration-enabling development planning.
  • The company's pipeline also includes TGR-63 targeting amyloid plaques & early-stage programs for neurodegeneration, tau proteins, & metabolic dysfunctions.